Highlands Oncology Group

Fayetteville, AR, United States

Highlands Oncology Group

Fayetteville, AR, United States

Time filter

Source Type

News Article | April 17, 2017
Site: co.newswire.com

Highlands Oncology Group, Northwest Arkansas’ leading cancer treatment provider, is sponsoring the second annual Northwest Arkansas METSquerade, benefiting metastatic breast cancer research. The masquerade event will be from 6 p.m. to 11 p.m. on April 8th at the John Q Hammons Center in Rogers. Funds raised will benefit METAvivor, an organization which dedicates all proceeds toward metastatic breast cancer research. METAvivor is the only organization in the US that exclusively funds metastatic breast cancer research through a scientific peer-review process, according to their website. The group awards grants to individuals who are actively engaged in areas of metastatic breast cancer research and whose proposals show distinct promise in making a difference for the stage four breast cancer community. The mission of the group is to transition metastatic breast cancer from a terminal diagnosis to a chronic, manageable disease with a decent quality of life. Metastatic breast cancer (also called stage four or advanced breast cancer) is not a specific type of breast cancer, but rather the most advanced stage of breast cancer, according to the Susan G. Komen organization. Metastatic breast cancer is breast cancer that has spread beyond the breast to other organs in the body. For women in the U.S., breast cancer death rates are higher than those for any other cancer, besides lung cancer, according to breastcancer.org, a non-profit organization dedicated to breast cancer awareness. As such, Highlands Oncology Group continually hosts and participates in clinical trials and is actively involved in research on treatment options for breast cancer, and many other cancers. Aside from skin cancer, breast cancer is the most common cancer among American women, according to the American Cancer Society (ACS). In 2017, about 252,710 new cases of invasive breast cancer will be diagnosed and about 40,610 women will die from breast cancer in the United States, according to the ACS. As the leading cancer treatment and research facility in Northwest Arkansas, Highlands Oncology Group is dedicated to the advancement of cancer treatment and to providing patients with the best possible care and results. Highlands Oncology Group is honored to sponsor this important event. For more information, please visit: www.nwamets.org. Highlands Oncology Group is a state-of-the-art facility, with a world-class team of specialists, that is committed to providing premier cancer treatment and to enhancing the quality of life of patients and their loved ones. Highlands Oncology group provides this in a friendly, comfortable environment conveniently located in Northwest Arkansas. Highlands offers the latest technology of diagnostic imaging and radiation therapies, on-site labs, a pharmacy and an infusion center. They also offer access to clinical trials, multidisciplinary clinics and support groups. Highlands Oncology Group is helping patients win the battle against cancer, every day!


Highlands Oncology Group Nominated For Award Due to Implementation of New Technology Matching Patients With Eligible Clinical Trials Highlands Oncology Group, Northwest Arkansas’ leading cancer treatment provider, has been nominated as a shortlisted contender for “Best Sponsor-Focused Technological Development” by the Clinical and Research Excellence (CARE) Awards. Highlands Oncology Group was nominated for their use of IBM Watson to electronically screen patients for qualifying clinical trials in which they may be eligible. IBM Watson is a technology platform that uses natural language processing and machine learning to reveal insights from large amounts of unstructured data, according to the International Business Machines (IBM) website. Watson for Clinical Trial Matching enhances clinicians’ ability to find the potential list of clinical trials for which patients may be eligible, increases the likelihood that patients are offered the option of a clinical trial for treatment and increases clinical trial fulfillment through effective patient recruitment, according to the IBM website. In 2016, there will be an estimated 1,685, 210 new cancer cases in the United States, according to the American Cancer Society, as such, clinical trial participation is imperative to the advancement of cancer treatment. Highlands Oncology Group was nominated in congruence with Novartis Oncology and IBM Watson Health for their collaboration in the clinical trial matching program. Winners of the 2017 CARE Awards, which recognize excellence across global clinical research, will be decided by a distinguished panel of industry experts and announced at a ceremony on April 5 in Boston, according to the CARE Awards website. As the leading cancer treatment and research facility in Northwest Arkansas, Highlands Oncology Group is dedicated to the advancement of cancer treatment and to providing patients with the best possible care and results. Highlands Oncology Group is a state-of-the-art facility, with a world-class team of specialists, that is committed to providing premier cancer treatment and to enhancing the quality of life of patients and their loved ones. Highlands Oncology group provides this in a friendly, comfortable environment conveniently located in Northwest Arkansas. Highlands offers the latest technology of diagnostic imaging and radiation therapies, on-site labs, a pharmacy and an infusion center. They also offer access to clinical trials, multidisciplinary clinics and support groups. Highlands Oncology Group is helping patients win the battle against cancer, every day!


News Article | April 17, 2017
Site: co.newswire.com

Highlands Oncology Group Awarded For Implementation Of New Technology Matching Patients With Eligible Clinical Trials Highlands Oncology Group, Northwest Arkansas’ leading cancer treatment provider, was awarded for “Best Sponsor-Focused Technological Development” at the second annual Clinical and Research Excellence (CARE) Awards. Highlands Oncology Group won for their use of IBM Watson to electronically screen patients for qualifying clinical trials. The group was presented the award at the 2017 CARE Awards on April 5 in Boston. The CARE Awards recognize excellence across global clinical research. Watson for Clinical Trial Matching enhances clinicians’ ability to find the potential list of clinical trials for which patients may be eligible, increases the likelihood that patients are offered the option of a clinical trial for treatment and increases clinical trial fulfillment through effective patient recruitment, according to the IBM website. “The Watson Clinical Trial Matching Team developed a solution to automate the screening of patient records by study staff to identify potential study participants,” according to the CARE Awards judges. “Cost, time and potential for error are all dramatically improved. This was a powerful, forward-looking approach anticipating the convergence of clinical care and clinical research driven by electronic health and medical information.” IBM Watson is a technology platform that uses natural language processing and machine learning to reveal insights from large amounts of unstructured data, according to the International Business Machines (IBM) website. In 2017, there will be an estimated 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the United States, according to the American Cancer Society. Approximately 40 percent of men and women will be diagnosed with cancer at some point during their lifetimes, according to the National Cancer Institute. As such, clinical trial participation is important to the advancement of cancer treatment. Highlands Oncology Group was awarded in unison with Novartis Oncology and IBM Watson Health for their collaboration in the clinical trial matching program. As the leading cancer treatment and research facility in Northwest Arkansas, Highlands Oncology Group is dedicated to the advancement of cancer treatment and to providing patients with the best possible care and results. To see the full list of winners for the 2017 CARE Awards, visit: https://ibiawards.com/careawards/2017-winners/ Highlands Oncology Group is a state-of-the-art facility, with a world-class team of specialists, that is committed to providing premier cancer treatment and to enhancing the quality of life of patients and their loved ones. Highlands Oncology group provides this in a friendly, comfortable environment conveniently located in Northwest Arkansas. Highlands offers the latest technology of diagnostic imaging and radiation therapies, on-site labs, a pharmacy and an infusion center. They also offer access to clinical trials, multidisciplinary clinics and support groups. Highlands Oncology Group is helping patients win the battle against cancer, every day!


Highlands Oncology Group Presented on Trial Matching Technology at Annual ASCO Meeting


News Article | May 30, 2017
Site: co.newswire.com

Anne Vanhook, of Highlands Oncology Group, Was Listed Among the Best Nurses in NWA Anne Vanhook, of Highlands Oncology Group, Northwest Arkansas’ leading cancer treatment provider, was included on the Northwest Arkansas Democrat Gazette’s annual list of top nurses in the region. The list was published in congruence with National Nurses Week. The list is published each year to celebrate the dedication of nurses in Northwest Arkansas, and nationwide. “There are many heroes who leave behind positive change because they deliver exceptional care to patients than what’s expected of them,” the article states. “These nurses have gone above and beyond to impact the lives of at least one of their patients, coworkers and their community, and they deserve to be recognized as one of the best nurses in Northwest Arkansas.” National Nurses Week begins each year on May 6 and ends on May 12, Florence Nightingale's birthday, according to the American Nurses Association (ANA). These permanent dates enhance planning and position National Nurses Week as an established recognition event. As of 1998, May 8 was designated as National Student Nurses Day, to be celebrated annually. And as of 2003, National School Nurse Day is celebrated on the Wednesday within National Nurses Week each year, according to the ANA. As the leading cancer treatment and research facility in Northwest Arkansas, Highlands Oncology Group is dedicated to the advancement of cancer treatment and to providing patients with the best possible care and results. Highlands Oncology Group is a state-of-the-art facility, with a world-class team of specialists, that is committed to providing premier cancer treatment and to enhancing the quality of life of patients and their loved ones. Highlands Oncology group provides this in a friendly, comfortable environment conveniently located in Northwest Arkansas. Highlands offers the latest technology of diagnostic imaging and radiation therapies, on-site labs, a pharmacy and an infusion center. They also offer access to clinical trials, multidisciplinary clinics and support groups. Highlands Oncology Group is helping patients win the battle against cancer, every day!


News Article | July 24, 2017
Site: co.newswire.com

Highlands Oncology Group Excited to Welcome Sarah W. Jewell, M.D., to Team


News Article | November 7, 2016
Site: co.newswire.com

Highlands Oncology Group Centers Are First In World to Conduct Trial on PDL-1 Immunotherapy and Radiation for Initial Head and Neck Cancer Treatment Highlands Oncology Group (HOG), Northwest Arkansas’ leading cancer research group, is the first cancer treatment group, globally, to open a new clinical trial which studies the use of PDL-1 immunotherapy in combination with radiation as the inaugural therapy for head and neck cancer. “Highlands is excited to be the first institute to open this global effort to bring immunotherapy to the forefront of care for patients in our community,” Dr. J. Thaddeus Beck, of HOG, said. “This program is an extension of our phase one development.” Cancers of the head and neck, which include cancers of the oral cavity, larynx, pharynx, salivary glands, and nose/nasal passages, account for approximately three percent of all malignancies in the United States, according to the National Cancer Institute. Tobacco and alcohol use are the most important risk factors for most head and neck cancers. In 2016, there will be an estimated 1,685,210 new cancer cases diagnosed and 595,690 cancer deaths in the U.S., according to the American Cancer Society. As such, HOG is committed to the betterment of cancer treatment. As the leading cancer treatment and research facility in Northwest Arkansas, Highlands Oncology Group is dedicated to the advancement of cancer treatment and to providing patients with the best possible care and results. Highlands Oncology Group is a state-of-the-art facility, with a world-class team of specialists, that is committed to providing premier cancer treatment and to enhancing the quality of life of patients and their loved ones. Highlands Oncology group provides this in a friendly, comfortable environment conveniently located in Northwest Arkansas. Highlands offers the latest technology of diagnostic imaging and radiation therapies, on-site labs, a pharmacy and an infusion center. They also offer access to clinical trials, multidisciplinary clinics and support groups. Highlands Oncology Group is helping patients win the battle against cancer, every day! For more information, please visit: www.HighlandsOncologyGroup.com.


Highlands Oncology Group Will Collaborate To Research Immunotherapy For Ovarian Cancer


Beck J.T.,Highlands Oncology Group | Ismail A.,University of Arkansas for Medical Sciences | Tolomeo C.,University of Arkansas for Medical Sciences
Cancer Treatment Reviews | Year: 2014

Squamous cell lung carcinoma accounts for approximately 30% of all non-small cell lung cancers (NSCLCs). Despite progress in the understanding of the biology of cancer, cytotoxic chemotherapy remains the standard of care for patients with squamous cell lung carcinoma, but the prognosis is generally poor. The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is one of the most commonly activated signaling pathways in cancer, leading to cell proliferation, survival, and differentiation. It has therefore become a major focus of clinical research. Various alterations in the PI3K/AKT/mTOR pathway have been identified in squamous cell lung carcinoma and a number of agents targeting these alterations are in clinical development for use as single agents and in combination with other targeted and conventional treatments. These include pan-PI3K inhibitors, isoform-specific PI3K inhibitors, AKT inhibitors, mTOR inhibitors, and dual PI3K/mTOR inhibitors. These agents have demonstrated antitumor activity in preclinical models of NSCLC and preliminary clinical evidence is also available for some agents. This review will discuss the role of the PI3K/AKT/mTOR pathway in cancer and how the discovery of genetic alterations in this pathway in patients with squamous cell lung carcinoma can inform the development of targeted therapies for this disease. An overview of ongoing clinical trials investigating PI3K/AKT/mTOR pathway inhibitors in squamous cell lung carcinoma will also be included. © 2014 Elsevier Ltd.


Highlands Oncology Group Proudly Congratulates Nurses on Achieving Certification in Oncology Nursing

Loading Highlands Oncology Group collaborators
Loading Highlands Oncology Group collaborators